 Manali Kamdar
Concepts (225)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphoma, Large B-Cell, Diffuse | 24 | 2026 | 192 | 8.290 |
Why?
| | Immunotherapy, Adoptive | 25 | 2026 | 337 | 4.890 |
Why?
| | Lymphoma, Mantle-Cell | 13 | 2026 | 32 | 3.980 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 38 | 2026 | 1953 | 3.490 |
Why?
| | Leukemia, Lymphocytic, Chronic, B-Cell | 13 | 2026 | 76 | 3.320 |
Why?
| | Lymphoma, B-Cell | 9 | 2025 | 132 | 2.840 |
Why?
| | Neoplasm Recurrence, Local | 22 | 2026 | 1137 | 2.390 |
Why?
| | Hematopoietic Stem Cell Transplantation | 13 | 2026 | 674 | 2.380 |
Why?
| | Rituximab | 19 | 2026 | 209 | 2.110 |
Why?
| | Lymphoma | 4 | 2024 | 232 | 1.930 |
Why?
| | Bendamustine Hydrochloride | 8 | 2026 | 17 | 1.460 |
Why?
| | Immunoconjugates | 6 | 2026 | 132 | 1.330 |
Why?
| | Antigens, CD19 | 11 | 2026 | 129 | 1.250 |
Why?
| | Lymphoma, Follicular | 4 | 2026 | 56 | 1.230 |
Why?
| | Antibodies, Bispecific | 3 | 2026 | 64 | 1.180 |
Why?
| | Neoplasms, Second Primary | 2 | 2020 | 100 | 1.130 |
Why?
| | Mediastinal Neoplasms | 4 | 2025 | 51 | 0.950 |
Why?
| | Lymphoma, B-Cell, Marginal Zone | 3 | 2026 | 19 | 0.940 |
Why?
| | Neurotoxicity Syndromes | 1 | 2025 | 38 | 0.910 |
Why?
| | Burkitt Lymphoma | 5 | 2025 | 62 | 0.870 |
Why?
| | Antibodies, Monoclonal | 6 | 2023 | 1519 | 0.840 |
Why?
| | Neutropenia | 2 | 2023 | 155 | 0.840 |
Why?
| | Antibodies, Monoclonal, Humanized | 7 | 2025 | 985 | 0.830 |
Why?
| | Cancer Vaccines | 1 | 2025 | 160 | 0.820 |
Why?
| | Thrombocytopenia | 2 | 2023 | 205 | 0.810 |
Why?
| | Hodgkin Disease | 5 | 2024 | 171 | 0.760 |
Why?
| | Positron Emission Tomography Computed Tomography | 2 | 2024 | 117 | 0.760 |
Why?
| | Humans | 91 | 2026 | 144261 | 0.740 |
Why?
| | Cyclophosphamide | 8 | 2025 | 266 | 0.710 |
Why?
| | Central Nervous System Neoplasms | 4 | 2026 | 173 | 0.680 |
Why?
| | Vincristine | 7 | 2025 | 140 | 0.670 |
Why?
| | Aged | 38 | 2026 | 25850 | 0.650 |
Why?
| | Adult | 47 | 2026 | 40262 | 0.650 |
Why?
| | Prognosis | 17 | 2026 | 4278 | 0.640 |
Why?
| | Antineoplastic Agents | 7 | 2024 | 2192 | 0.630 |
Why?
| | Doxorubicin | 8 | 2025 | 397 | 0.620 |
Why?
| | Middle Aged | 41 | 2026 | 35762 | 0.610 |
Why?
| | Positron-Emission Tomography | 2 | 2018 | 323 | 0.610 |
Why?
| | Transplantation, Autologous | 7 | 2026 | 290 | 0.590 |
Why?
| | Bone Marrow | 3 | 2021 | 304 | 0.570 |
Why?
| | Programmed Cell Death 1 Receptor | 2 | 2017 | 264 | 0.550 |
Why?
| | Hematologic Neoplasms | 3 | 2025 | 161 | 0.550 |
Why?
| | Lymphoproliferative Disorders | 1 | 2018 | 57 | 0.540 |
Why?
| | Lymphoma, Non-Hodgkin | 3 | 2025 | 124 | 0.530 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2018 | 156 | 0.520 |
Why?
| | Lymphoma, Large-Cell, Anaplastic | 1 | 2017 | 22 | 0.510 |
Why?
| | Retrospective Studies | 24 | 2026 | 17009 | 0.470 |
Why?
| | Male | 42 | 2026 | 72035 | 0.450 |
Why?
| | Treatment Outcome | 25 | 2026 | 11643 | 0.440 |
Why?
| | Standard of Care | 3 | 2025 | 80 | 0.440 |
Why?
| | Female | 43 | 2026 | 77976 | 0.440 |
Why?
| | Aged, 80 and over | 20 | 2026 | 8243 | 0.430 |
Why?
| | Cancer Survivors | 1 | 2019 | 326 | 0.420 |
Why?
| | Pyrazines | 3 | 2025 | 92 | 0.410 |
Why?
| | Benzamides | 3 | 2025 | 224 | 0.400 |
Why?
| | Immunotherapy | 4 | 2025 | 652 | 0.350 |
Why?
| | Etoposide | 5 | 2025 | 166 | 0.330 |
Why?
| | Neoplasm, Residual | 3 | 2026 | 139 | 0.300 |
Why?
| | Follow-Up Studies | 7 | 2025 | 5389 | 0.290 |
Why?
| | Cell- and Tissue-Based Therapy | 3 | 2024 | 80 | 0.290 |
Why?
| | Dexamethasone | 2 | 2022 | 370 | 0.280 |
Why?
| | Kaplan-Meier Estimate | 6 | 2021 | 964 | 0.270 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 4 | 2024 | 279 | 0.270 |
Why?
| | Cord Blood Stem Cell Transplantation | 2 | 2020 | 103 | 0.270 |
Why?
| | Graft vs Host Disease | 3 | 2020 | 264 | 0.270 |
Why?
| | Transplantation Conditioning | 5 | 2021 | 186 | 0.270 |
Why?
| | Recurrence | 6 | 2026 | 1134 | 0.270 |
Why?
| | Brain Neoplasms | 1 | 2017 | 1318 | 0.260 |
Why?
| | Chlorambucil | 3 | 2025 | 10 | 0.260 |
Why?
| | Medical Oncology | 2 | 2020 | 331 | 0.240 |
Why?
| | Sulfonamides | 4 | 2024 | 580 | 0.240 |
Why?
| | Circulating Tumor DNA | 1 | 2026 | 43 | 0.230 |
Why?
| | Tissue Extracts | 1 | 2025 | 19 | 0.230 |
Why?
| | Proportional Hazards Models | 4 | 2023 | 1322 | 0.220 |
Why?
| | Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2024 | 39 | 0.220 |
Why?
| | Protein Kinase Inhibitors | 3 | 2026 | 968 | 0.220 |
Why?
| | Receptors, Antigen, T-Cell | 3 | 2026 | 668 | 0.210 |
Why?
| | Young Adult | 13 | 2026 | 13990 | 0.210 |
Why?
| | Lymphoma, T-Cell, Peripheral | 1 | 2024 | 20 | 0.200 |
Why?
| | Tumor Lysis Syndrome | 1 | 2023 | 9 | 0.200 |
Why?
| | Thiotepa | 2 | 2026 | 21 | 0.200 |
Why?
| | Prednisone | 4 | 2025 | 221 | 0.190 |
Why?
| | Treatment Failure | 1 | 2024 | 363 | 0.190 |
Why?
| | Neoplasm Grading | 2 | 2024 | 307 | 0.190 |
Why?
| | Neoplasm Staging | 4 | 2020 | 1461 | 0.190 |
Why?
| | Clinical Trials as Topic | 2 | 2025 | 1050 | 0.190 |
Why?
| | Pyrimidines | 2 | 2024 | 532 | 0.180 |
Why?
| | Killer Cells, Natural | 1 | 2025 | 467 | 0.180 |
Why?
| | Drug Resistance, Neoplasm | 5 | 2025 | 881 | 0.180 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2022 | 105 | 0.170 |
Why?
| | Leukemia, Myeloid, Acute | 3 | 2024 | 682 | 0.170 |
Why?
| | Tumor Microenvironment | 1 | 2025 | 732 | 0.170 |
Why?
| | SEER Program | 2 | 2019 | 224 | 0.170 |
Why?
| | Methotrexate | 1 | 2022 | 240 | 0.160 |
Why?
| | Disease Management | 3 | 2021 | 643 | 0.160 |
Why?
| | Piperidines | 1 | 2022 | 217 | 0.160 |
Why?
| | Cisplatin | 1 | 2022 | 334 | 0.160 |
Why?
| | Referral and Consultation | 1 | 2025 | 847 | 0.150 |
Why?
| | Societies, Medical | 2 | 2024 | 886 | 0.140 |
Why?
| | Risk Factors | 4 | 2023 | 10699 | 0.140 |
Why?
| | Antiviral Agents | 2 | 2021 | 767 | 0.140 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 3 | 2026 | 240 | 0.140 |
Why?
| | Survival Rate | 4 | 2026 | 2088 | 0.140 |
Why?
| | Pilot Projects | 1 | 2024 | 1867 | 0.140 |
Why?
| | Herpes Zoster | 1 | 2022 | 315 | 0.140 |
Why?
| | Pyrazoles | 1 | 2022 | 509 | 0.140 |
Why?
| | Leukemia, Hairy Cell | 1 | 2017 | 7 | 0.140 |
Why?
| | Combined Modality Therapy | 2 | 2018 | 1264 | 0.130 |
Why?
| | Leukemia, B-Cell | 1 | 2017 | 12 | 0.130 |
Why?
| | Radiopharmaceuticals | 1 | 2018 | 194 | 0.130 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2020 | 293 | 0.130 |
Why?
| | Prednisolone | 1 | 2017 | 66 | 0.130 |
Why?
| | Symptom Assessment | 1 | 2018 | 137 | 0.130 |
Why?
| | Adolescent | 7 | 2025 | 22281 | 0.130 |
Why?
| | Fatal Outcome | 1 | 2017 | 307 | 0.120 |
Why?
| | ROC Curve | 1 | 2018 | 612 | 0.120 |
Why?
| | Maintenance Chemotherapy | 2 | 2026 | 42 | 0.120 |
Why?
| | HIV Infections | 2 | 2021 | 3079 | 0.120 |
Why?
| | United States | 10 | 2024 | 15876 | 0.120 |
Why?
| | Survivors | 1 | 2019 | 516 | 0.120 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 382 | 0.110 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2017 | 230 | 0.110 |
Why?
| | Coronavirus Infections | 1 | 2020 | 377 | 0.110 |
Why?
| | Disease-Free Survival | 3 | 2021 | 768 | 0.110 |
Why?
| | Survival Analysis | 4 | 2020 | 1382 | 0.110 |
Why?
| | T-Lymphocytes | 1 | 2023 | 1982 | 0.110 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2020 | 1705 | 0.100 |
Why?
| | Immunosuppressive Agents | 1 | 2018 | 846 | 0.100 |
Why?
| | Incidence | 1 | 2020 | 2870 | 0.100 |
Why?
| | Biological Products | 2 | 2026 | 251 | 0.090 |
Why?
| | Healthcare Disparities | 1 | 2018 | 725 | 0.090 |
Why?
| | Europe | 2 | 2024 | 412 | 0.090 |
Why?
| | Delivery of Health Care | 1 | 2018 | 940 | 0.090 |
Why?
| | Cell Differentiation | 1 | 2019 | 2048 | 0.090 |
Why?
| | Prevalence | 1 | 2018 | 2815 | 0.080 |
Why?
| | Salvage Therapy | 2 | 2025 | 162 | 0.080 |
Why?
| | Proto-Oncogene Proteins c-myc | 2 | 2023 | 167 | 0.080 |
Why?
| | Gene Rearrangement | 2 | 2021 | 155 | 0.070 |
Why?
| | Remission Induction | 2 | 2020 | 306 | 0.070 |
Why?
| | Infant, Newborn | 1 | 2019 | 6424 | 0.070 |
Why?
| | Immunophenotyping | 2 | 2020 | 322 | 0.070 |
Why?
| | Transplantation, Homologous | 2 | 2020 | 415 | 0.060 |
Why?
| | Infant | 3 | 2019 | 10022 | 0.060 |
Why?
| | Mutation | 3 | 2025 | 4085 | 0.060 |
Why?
| | Ataxia Telangiectasia Mutated Proteins | 1 | 2025 | 69 | 0.060 |
Why?
| | Clarithromycin | 2 | 1997 | 25 | 0.060 |
Why?
| | Child, Preschool | 3 | 2019 | 11774 | 0.060 |
Why?
| | Maximum Tolerated Dose | 1 | 2024 | 212 | 0.050 |
Why?
| | Acrylamides | 1 | 2024 | 70 | 0.050 |
Why?
| | Lactate Dehydrogenases | 1 | 2023 | 6 | 0.050 |
Why?
| | Aniline Compounds | 1 | 2024 | 119 | 0.050 |
Why?
| | Genetic Therapy | 1 | 2026 | 313 | 0.050 |
Why?
| | Lung Neoplasms | 1 | 2017 | 2637 | 0.050 |
Why?
| | North America | 1 | 2023 | 310 | 0.050 |
Why?
| | Myelodysplastic Syndromes | 1 | 2024 | 147 | 0.050 |
Why?
| | Biomarkers, Tumor | 2 | 2020 | 1313 | 0.050 |
Why?
| | Retreatment | 1 | 2022 | 77 | 0.050 |
Why?
| | Stem Cell Transplantation | 1 | 2023 | 191 | 0.050 |
Why?
| | Time-to-Treatment | 1 | 2024 | 240 | 0.050 |
Why?
| | Recombinant Fusion Proteins | 1 | 2025 | 674 | 0.050 |
Why?
| | Bleomycin | 1 | 2023 | 253 | 0.050 |
Why?
| | Injections, Spinal | 1 | 2022 | 120 | 0.040 |
Why?
| | Benzodiazepines | 1 | 2023 | 165 | 0.040 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2025 | 529 | 0.040 |
Why?
| | L-Lactate Dehydrogenase | 1 | 2021 | 115 | 0.040 |
Why?
| | Child | 3 | 2019 | 22537 | 0.040 |
Why?
| | Indoles | 1 | 2024 | 501 | 0.040 |
Why?
| | Immunization, Passive | 1 | 2020 | 87 | 0.040 |
Why?
| | Cohort Studies | 2 | 2021 | 5935 | 0.040 |
Why?
| | United Kingdom | 1 | 2021 | 336 | 0.040 |
Why?
| | Genomics | 1 | 2025 | 833 | 0.040 |
Why?
| | Lymphocyte Activation | 1 | 2024 | 1126 | 0.040 |
Why?
| | Organizations, Nonprofit | 1 | 2020 | 17 | 0.040 |
Why?
| | Australia | 1 | 2021 | 286 | 0.040 |
Why?
| | Canada | 1 | 2021 | 428 | 0.040 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2025 | 1455 | 0.040 |
Why?
| | Central Nervous System | 1 | 2021 | 281 | 0.040 |
Why?
| | Drug Therapy, Combination | 1 | 2021 | 1044 | 0.040 |
Why?
| | Gene Expression Profiling | 1 | 2025 | 1782 | 0.040 |
Why?
| | Public Health Surveillance | 1 | 2018 | 83 | 0.030 |
Why?
| | Myeloablative Agonists | 1 | 2018 | 23 | 0.030 |
Why?
| | Vidarabine | 1 | 2018 | 32 | 0.030 |
Why?
| | Comorbidity | 1 | 2023 | 1646 | 0.030 |
Why?
| | Whole-Body Irradiation | 1 | 2018 | 76 | 0.030 |
Why?
| | Practice Guidelines as Topic | 1 | 2026 | 1559 | 0.030 |
Why?
| | Lymphocytes | 1 | 2020 | 382 | 0.030 |
Why?
| | Fetal Blood | 1 | 2020 | 342 | 0.030 |
Why?
| | Disease Progression | 1 | 2025 | 2840 | 0.030 |
Why?
| | Cytodiagnosis | 1 | 2017 | 31 | 0.030 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2020 | 199 | 0.030 |
Why?
| | Immunoglobulin Heavy Chains | 1 | 2017 | 85 | 0.030 |
Why?
| | Betacoronavirus | 1 | 2020 | 285 | 0.030 |
Why?
| | Chronic Disease | 1 | 2023 | 1812 | 0.030 |
Why?
| | Tonsillitis | 1 | 1997 | 8 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2021 | 1533 | 0.030 |
Why?
| | Pharyngitis | 1 | 1997 | 25 | 0.030 |
Why?
| | Lymph Nodes | 1 | 2020 | 502 | 0.030 |
Why?
| | Streptococcus pyogenes | 1 | 1997 | 41 | 0.030 |
Why?
| | Penicillins | 1 | 1997 | 61 | 0.030 |
Why?
| | Anti-Inflammatory Agents | 1 | 2020 | 474 | 0.030 |
Why?
| | Datasets as Topic | 1 | 2016 | 122 | 0.030 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2017 | 225 | 0.030 |
Why?
| | Immunohistochemistry | 1 | 2019 | 1715 | 0.030 |
Why?
| | Streptococcal Infections | 1 | 1997 | 168 | 0.030 |
Why?
| | Radiotherapy | 1 | 2015 | 206 | 0.030 |
Why?
| | Insurance Coverage | 1 | 2016 | 238 | 0.030 |
Why?
| | Propensity Score | 1 | 2016 | 367 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2017 | 1487 | 0.020 |
Why?
| | Amoxicillin | 1 | 1993 | 35 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2015 | 1304 | 0.020 |
Why?
| | Gene Expression | 1 | 2017 | 1487 | 0.020 |
Why?
| | Pandemics | 1 | 2020 | 1682 | 0.020 |
Why?
| | Otitis Media | 1 | 1993 | 181 | 0.020 |
Why?
| | Quality of Life | 1 | 2022 | 3166 | 0.020 |
Why?
| | Prospective Studies | 1 | 2022 | 7970 | 0.020 |
Why?
| | Registries | 1 | 2016 | 2382 | 0.020 |
Why?
| | Anti-Bacterial Agents | 1 | 1997 | 1906 | 0.020 |
Why?
| | Time Factors | 1 | 2015 | 7155 | 0.010 |
Why?
| | Suspensions | 1 | 1993 | 29 | 0.010 |
Why?
| | Family Practice | 1 | 1997 | 403 | 0.010 |
Why?
| | Intestinal Absorption | 1 | 1993 | 103 | 0.010 |
Why?
| | Single-Blind Method | 1 | 1993 | 311 | 0.010 |
Why?
| | Administration, Oral | 1 | 1993 | 847 | 0.010 |
Why?
| | Acute Disease | 1 | 1993 | 1028 | 0.000 |
Why?
| | Body Weight | 1 | 1993 | 976 | 0.000 |
Why?
|
|
Kamdar's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|